Annual SG&A
$34.83 M
+$7.31 M+26.55%
31 December 2023
Summary:
Keros Therapeutics annual selling, general & administrative expenses is currently $34.83 million, with the most recent change of +$7.31 million (+26.55%) on 31 December 2023. During the last 3 years, it has risen by +$22.04 million (+172.20%). KROS annual SG&A is now at all-time high.KROS Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$9.82 M
-$141.00 K-1.42%
30 September 2024
Summary:
Keros Therapeutics quarterly selling, general & administrative expenses is currently $9.82 million, with the most recent change of -$141.00 thousand (-1.42%) on 30 September 2024. Over the past year, it has increased by +$672.00 thousand (+7.35%). KROS quarterly SG&A is now -4.73% below its all-time high of $10.31 million, reached on 31 March 2024.KROS Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.80 B
-$181.57 M-11.23%
30 September 2024
Summary:
Keros Therapeutics TTM selling, general & administrative expenses is currently -$1.80 billion, with the most recent change of -$181.57 million (-11.23%) on 30 September 2024. Over the past year, it has dropped by -$1.83 billion (-5579.61%). KROS TTM SG&A is now -9052.75% below its all-time high of $39.19 million, reached on 30 September 2024.KROS TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KROS Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +26.6% | +7.3% | -5579.6% |
| 3 y3 years | +172.2% | +83.0% | -9608.9% |
| 5 y5 years | +2104.7% | +910.3% | -10000.0% |
KROS Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +172.2% | -4.7% | +83.0% | -400.6% | at low |
| 5 y | 5 years | at high | +2104.7% | -4.7% | +910.3% | -9052.8% | at low |
| alltime | all time | at high | +2104.7% | -4.7% | +1900.0% | -9052.8% | at low |
Keros Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $9.82 M(-1.4%) | $39.19 M(+1.7%) |
| June 2024 | - | $9.96 M(-3.4%) | $38.52 M(+3.1%) |
| Mar 2024 | - | $10.31 M(+13.2%) | $37.36 M(+7.3%) |
| Dec 2023 | $34.83 M(+26.6%) | $9.11 M(-0.5%) | $34.83 M(+6.1%) |
| Sept 2023 | - | $9.15 M(+3.9%) | $32.82 M(+7.2%) |
| June 2023 | - | $8.80 M(+13.2%) | $30.61 M(+4.6%) |
| Mar 2023 | - | $7.78 M(+9.7%) | $29.25 M(+6.3%) |
| Dec 2022 | $27.52 M(+29.0%) | $7.09 M(+2.2%) | $27.52 M(+4.0%) |
| Sept 2022 | - | $6.94 M(-6.8%) | $26.46 M(+6.3%) |
| June 2022 | - | $7.45 M(+23.1%) | $24.89 M(+7.7%) |
| Mar 2022 | - | $6.05 M(+0.2%) | $23.10 M(+8.3%) |
| Dec 2021 | $21.33 M | $6.03 M(+12.5%) | $21.33 M(+12.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $5.37 M(-5.2%) | $18.91 M(+10.6%) |
| June 2021 | - | $5.66 M(+32.4%) | $17.10 M(+13.3%) |
| Mar 2021 | - | $4.27 M(+18.2%) | $15.09 M(+17.9%) |
| Dec 2020 | $12.80 M(+301.9%) | $3.62 M(+1.8%) | $12.80 M(+24.9%) |
| Sept 2020 | - | $3.55 M(-2.7%) | $10.25 M(+33.7%) |
| June 2020 | - | $3.65 M(+84.6%) | $7.67 M(+64.2%) |
| Mar 2020 | - | $1.98 M(+85.3%) | $4.67 M(+46.7%) |
| Dec 2019 | $3.18 M(+101.5%) | $1.07 M(+9.8%) | $3.18 M(+50.4%) |
| Sept 2019 | - | $972.00 K(+48.6%) | $2.12 M(+84.9%) |
| June 2019 | - | $654.00 K(+33.2%) | $1.15 M(+133.2%) |
| Mar 2019 | - | $491.00 K | $491.00 K |
| Dec 2018 | $1.58 M | - | - |
FAQ
- What is Keros Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Keros Therapeutics?
- What is Keros Therapeutics annual SG&A year-on-year change?
- What is Keros Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Keros Therapeutics?
- What is Keros Therapeutics quarterly SG&A year-on-year change?
- What is Keros Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Keros Therapeutics?
- What is Keros Therapeutics TTM SG&A year-on-year change?
What is Keros Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of KROS is $34.83 M
What is the all time high annual SG&A for Keros Therapeutics?
Keros Therapeutics all-time high annual selling, general & administrative expenses is $34.83 M
What is Keros Therapeutics annual SG&A year-on-year change?
Over the past year, KROS annual selling, general & administrative expenses has changed by +$7.31 M (+26.55%)
What is Keros Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of KROS is $9.82 M
What is the all time high quarterly SG&A for Keros Therapeutics?
Keros Therapeutics all-time high quarterly selling, general & administrative expenses is $10.31 M
What is Keros Therapeutics quarterly SG&A year-on-year change?
Over the past year, KROS quarterly selling, general & administrative expenses has changed by +$672.00 K (+7.35%)
What is Keros Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of KROS is -$1.80 B
What is the all time high TTM SG&A for Keros Therapeutics?
Keros Therapeutics all-time high TTM selling, general & administrative expenses is $39.19 M
What is Keros Therapeutics TTM SG&A year-on-year change?
Over the past year, KROS TTM selling, general & administrative expenses has changed by -$1.83 B (-5579.61%)